Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10967436 | Vaccine | 2013 | 6 Pages |
Abstract
When compared to the HBsAg-Eng three-dose regimen given at 0, 1, and 6Â months, HBsAg-1018 demonstrated superior seroprotection with only two doses at 0 and 1Â month. The safety profile of HBsAg-1018 was comparable to that of the licensed vaccine, HBsAg-Eng. HBsAg-1018 would provide a significant public health contribution toward the prevention of hepatitis B infection.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
William L. Heyward, Michael Kyle, Joseph Blumenau, Matthew Davis, Keith Reisinger, Martin L. Kabongo, Sean Bennett, Robert S. Janssen, Hamid Namini, J. Tyler Martin,